Sepetaprost is an investigational new drug that is being evaluated for the treatment of open angle glaucoma and ocular hypertension.[1] It is an agonist of the prostaglandin EP3 and F receptors.[2]
Clinical data | |
---|---|
Other names | STN-1012600 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H36F2O6 |
Molar mass | 482.565 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Sepetaprost - Santen Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
- ^ Sharif NA, Odani-Kawabata N, Lu F, Pinchuk L (April 2023). "FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma". Experimental Eye Research. 229: 109415. doi:10.1016/j.exer.2023.109415. PMID 36803996.